<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004400</url>
  </required_header>
  <id_info>
    <org_study_id>199/13251</org_study_id>
    <secondary_id>CDUMS-FDR001397</secondary_id>
    <nct_id>NCT00004400</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether physiologic testosterone replacement can increase fat-free&#xD;
      mass, therefore contributing to weight maintenance, improved muscle function, and quality of&#xD;
      life in HIV-infected women.&#xD;
&#xD;
      II. Examine the mechanism of testosterone-induced increase in fat-free mass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are&#xD;
      randomized to one of three arms.&#xD;
&#xD;
      Arm I: Patients receive two placebo transdermal patches applied twice a week (every 3-4&#xD;
      days).&#xD;
&#xD;
      Arm II: Patients receive one testosterone transdermal patch and one placebo transdermal patch&#xD;
      applied twice a week (every 3-4 days).&#xD;
&#xD;
      Arm III: Patients receive two testosterone transdermal patches applied twice a week (every&#xD;
      3-4 days).&#xD;
&#xD;
      Patients receive 12 weeks of treatment in the absence of adverse reaction or health&#xD;
      deterioration. Patients are followed on day 1, every 2 weeks during treatment, and at the end&#xD;
      of the recovery period. Quality of life is assessed before treatment begins and at weeks 6&#xD;
      and 12.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1997</start_date>
  <completion_date>September 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">56</enrollment>
  <condition>HIV Infections</condition>
  <condition>Cachexia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Histologically confirmed premenopausal HIV-positive women who have experienced 5-15%&#xD;
             weight loss&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Endocrine therapy: At least 3 months since megestrol At least 3 months since anabolic&#xD;
             or androgenic steroids At least 3 months since oral contraceptives At least 3 months&#xD;
             since Depo-Provera No concurrent hormone replacement therapy&#xD;
&#xD;
          -  Other: Concurrent retroviral or protease inhibitors allowed, dosage must be stable At&#xD;
             least 3 months since ketoconazole At least 6 weeks since the initiation of protease&#xD;
             inhibitors&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Hepatic: No significant liver disease SGOT/SGPT no greater than 3 times upper limit of&#xD;
             normal (ULN) Alkaline phosphatase no greater than 3 times ULN Bilirubin no greater&#xD;
             than 2 mg/dL No medical complications due to alcohol abuse&#xD;
&#xD;
          -  Renal: Not specified&#xD;
&#xD;
          -  Cardiovascular: No significant cardiovascular disease No uncontrolled hypertension&#xD;
&#xD;
          -  Other: Testosterone level (early morning) less than 30 ng/dL Normal gastrointestinal&#xD;
             function as indicated by: Absence of diarrhea Normal D-xylose absorption test No acute&#xD;
             opportunistic infections or infectious illness No malignant disease No history of&#xD;
             breast cancer No history of endometrial cancer No fever of known or unknown origin No&#xD;
             unremitting diarrhea defined as: At least 4 watery stools per day OR More than 4&#xD;
             watery stools recently OR Acute change in stool habit with fever No significant&#xD;
             respiratory disease No diabetes No illicit drugs within the past 6 months No history&#xD;
             of hyperandrogenic disorders such as: Hirsutism Polycystic ovary disease Not pregnant&#xD;
             or lactating&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalender Bhasin</last_name>
    <role>Study Chair</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles R. Drew University of Medicine and Science</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles County Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1998</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>cachexia</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>human immunodeficiency virus infection</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>nutrition</keyword>
  <keyword>quality of life</keyword>
  <keyword>rare disease</keyword>
  <keyword>viral infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

